How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) issued its quarterly earnings results on Thursday, November, 11th. The technology company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.15 by $0.41. The technology company earned $16.34 million during the quarter, compared to analysts' expectations of $12.45 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 97.03% and a negative net margin of 147.90%. During the same period in the prior year, the firm posted $0.15 earnings per share.

What other stocks do shareholders of Opiant Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA) , AcelRx Pharmaceuticals (ACRX) , Sangamo Therapeutics (SGMO) , Synchrony Financial (SYF) , Vodafone Group Public (VOD) , Agenus (AGEN) , Aldeyra Therapeutics (ALDX) , Aurinia Pharmaceuticals (AUPH) , Corbus Pharmaceuticals (CRBP) and CyberArk Software (CYBR) .

NASDAQ:OPNT

Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free OPNT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $20.03
▼
$21.10
52-Week Range: N/A

Volume: 562,700 shs
Average Volume: 77,920 shs
Market Capitalization: $108.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Opiant Pharmaceuticals alerts:

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Opiant Pharmaceuticals Stock (NASDAQ:OPNT)

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

Click here to find out that this 8,788% cryptocurrency is.

OPNT Stock News Headlines

April 18, 2024 | investing.com

Hikma Pharmaceuticals PLC ADR (HKMPY)

January 31, 2024 | forbes.com

Ionis Pharmaceuticals

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

May 24, 2023 | msn.com

UPDATE 2-US FDA approves Opiant's spray for reversing opioid-related overdoses

May 23, 2023 | msn.com

REFILE-US FDA approves Opiant's overdose reversal spray

March 3, 2023 | msn.com

Indivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfolio

February 22, 2023 | finance.yahoo.com

Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership, institutions own 33%

February 7, 2023 | finance.yahoo.com

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

January 26, 2023 | seekingalpha.com

Horizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update)

January 19, 2023 | finance.yahoo.com

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose

January 14, 2023 | thetimes.co.uk

Dechra Pharmaceuticals defies cooling pets market

January 13, 2023 | seekingalpha.com

Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In

January 7, 2023 | businesswire.com

OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant ...

November 22, 2022 | finance.yahoo.com

Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose

November 15, 2022 | benzinga.com

OPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant Pharmaceuticals

November 15, 2022 | benzinga.com

EQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNT

November 14, 2022 | benzinga.com

Shareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with Indivior

November 14, 2022 | benzinga.com

OPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to Shareholders

November 14, 2022 | nasdaq.com

Indivior To Buy Opiant For $145 Mln In Cash

November 14, 2022 | seekingalpha.com

Opiant surges 123% as Indivior set to acquire overdose therapy maker for $145M

November 14, 2022 | marketwatch.com

Opiant Pharmaceuticals Shares Surge Premarket on Takeover by Indivior >OPNT

November 14, 2022 | finance.yahoo.com

Indivior PLC to Acquire Opiant Pharmaceuticals

November 14, 2022 | finance.yahoo.com

Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results

November 14, 2022 | finance.yahoo.com

Narcan Owner Opiant to Be Acquired by Indivior for $145 Million

November 2, 2022 | finance.yahoo.com

The past five years for Opiant Pharmaceuticals (NASDAQ:OPNT) investors has not been profitable

October 27, 2022 | finance.yahoo.com

Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022

See More Headlines

Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/11/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:OPNT
CUSIP: N/A
CIK: 1108924
Web: www.opiant.com
Phone: (310) 598-5410
Fax: 917-322-2105
Employees: 37
Year Founded: 2009

Profitability

EPS (Most Recent Fiscal Year): ($6.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $3.01 million
Net Margins: -147.90%
Pretax Margin: -147.84%
Return on Equity: -97.03%
Return on Assets: -59.66%

Debt

Debt-to-Equity Ratio: 0.60
Current Ratio: 5.48
Quick Ratio: 5.48

Sales & Book Value

Annual Sales: $47.78 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 24.75
Book Value: $9.92 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 5,270,000
Free Float: 3,865,000
Market Cap: $108.83 million
Optionable: Not Optionable
Beta: 0.84

Social Links

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Roger Crystal
President, Chief Executive Officer & Director
David D. O'Toole
Chief Financial Officer & Secretary
Phil Skolnick
Chief Scientific Officer
Mark Jason H. Ellison
Chief Development Officer
Matthew R. Ruth
Chief Commercial Officer

Key Competitors

View All Competitors

OPNT Stock Analysis - Frequently Asked Questions

How were Opiant Pharmaceuticals' earnings last quarter?: Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) issued its quarterly earnings results on Thursday, November, 11th. The technology company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.15 by $0.41. The technology company earned $16.34 million during the quarter, compared to analysts' expectations of $12.45 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 97.03% and a negative net margin of 147.90%. During the same period in the prior year, the firm posted $0.15 earnings per share.
What other stocks do shareholders of Opiant Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Synchrony Financial (SYF), Vodafone Group Public (VOD), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and CyberArk Software (CYBR).

This page (NASDAQ:OPNT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis

About Opiant Pharmaceuticals Stock (NASDAQ:OPNT)

OPNT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

OPNT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info